Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 13 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more

Conditions: HIV Infection
Interventions: Atazanavir + Ritonavir + Combivir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: West Palm Beach, Florida • Houston, Texas

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Sargramostim, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: Los Angeles, California • Farmington, Connecticut • Miami, Florida + 3 more

Conditions: Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions: Zidovudine, Tocilizumab, Valganciclovir (VGC); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: HIV Infections
Interventions: Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: San Francisco, California • Fort Lauderdale, Florida • Fort Myers, Florida + 5 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Harbor City, California • Los Angeles, California • San Diego, California + 19 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: New York, New York

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Pyrimethamine, Leucovorin calcium, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: HIV Infections
Interventions: Zidovudine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 30
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 21 more

Conditions: HIV Infection
Interventions: Nelfinavir mesylate, 625 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 12 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 2 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Search by objective public record fields.

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women

A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia